Opinion
Video
Author(s):
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
OncLive’s May Roundup of Key FDA Approvals in Oncology
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC
FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma